

FORM PTO-1390 (REV 10-94)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 10242-32	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) <b>09/600125</b>	
INTERNATIONAL APPLICATION NO. PCT/CA99/00005		INTERNATIONAL FILING DATE 13 January 1999		PRIORITY DATE CLAIMED 13 January 1998	
TITLE OF INVENTION <b>Composition Containing Propargylamine for Enhancing Cancer Therapy</b>					
APPLICANT(S) FOR DO/EO/US <b>R.C. Warrington, I.A. Paterson and A.A. Boulton</b>					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1.	<input checked="" type="checkbox"/>	This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.			
2.	<input type="checkbox"/>	This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.			
3.	<input type="checkbox"/>	This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).			
4.	<input checked="" type="checkbox"/>	A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.			
5.	<input checked="" type="checkbox"/>	A copy of the International Application as filed (35 U.S.C. 371(c)(2))			
	(a)	<input type="checkbox"/>	is transmitted herewith (required only if not transmitted by the International Bureau).		
	(b)	<input checked="" type="checkbox"/>	has been transmitted by the International Bureau.		
	(c)	<input type="checkbox"/>	is not required, as the application was filed in the United States Receiving Office (RO/US)		
6.	<input type="checkbox"/>	A translation of the International Application into English (35 U.S.C. 371(c)(2)).			
7.	<input type="checkbox"/>	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))			
	(a)	<input type="checkbox"/>	are transmitted herewith (required only if not transmitted by the International Bureau).		
	(b)	<input type="checkbox"/>	have been transmitted by the International Bureau.		
	(c)	<input type="checkbox"/>	have not been made; however, the time limit for making such amendments has NOT expired.		
	(d)	<input type="checkbox"/>	have not been made and will not be made.		
8.	<input type="checkbox"/>	A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).			
9.	<input type="checkbox"/>	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).			
10.	<input type="checkbox"/>	A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).			
Items 11. to 16. below concern document(s) or information included:					
11.	<input type="checkbox"/>	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.			
12.	<input type="checkbox"/>	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.			
13.	<input checked="" type="checkbox"/>	A FIRST preliminary amendment.			
	<input type="checkbox"/>	A SECOND or SUBSEQUENT preliminary amendment.			
14.	<input type="checkbox"/>	A SUBSTITUTE SPECIFICATION.			
15.	<input type="checkbox"/>	A CHANGE OF POWER OF ATTORNEY AND/OR ADDRESS LETTER.			
16.	<input type="checkbox"/>	Other items or information: - An executed Small Entity Declaration			

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <div style="font-size: 24pt; font-weight: bold;">09/600125</div>		INTERNATIONAL APPLICATION NO. PCT/CA99/00005		ATTORNEY'S DOCKET NUMBER 10242-32	
---	--	---	--	--------------------------------------	--

17. <input checked="" type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):</b> Search Report has been prepared by the EPO or JPO \$910.00  International preliminary examination fee paid to USPTO (37 CFR 1.482) \$700.00  No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$770.00  Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1,040.00  International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$96.00  <div style="text-align: right;"><b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b></div>				<b>CALCULATIONS</b> <span style="float: right;">PTO USE ONLY</span>          <div style="text-align: right;"><b>\$910.00</b></div>	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
<b>CLAIMS</b>	<b>NUMBER FILED</b>	<b>NUMBER EXTRA</b>	<b>RATE</b>		
Total Claims	36 - 20 =		x \$22.00	\$ deferred	
Independent Claims	4 - 3 =		x \$80.00	\$ deferred	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00	\$	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$ 910.00	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$	
<b>SUBTOTAL =</b>				\$ 910.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
<b>TOTAL NATIONAL FEE =</b>				\$	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$	
<b>TOTAL FEES ENCLOSED =</b>				\$910.00	
				Amount to be refunded	\$
				charged	\$

a. ☒ a check in the amount of \$910.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. 02-2095 in the amount of \$\_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-2095. A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

Signature  
 Micheline Gravelle  
 Name  
 40,261  
 Registration No.

SEND ALL CORRESPONDENCE TO:  
 Micheline Gravelle  
 Bereskin & Parr  
 Box 401, 40 King Street West  
 Toronto, Ontario, Canada M5H 3Y2

09/600125

Bereskin & Parr 

534 Rec'd PCT/PTC 12 JUL 2000

Barristers and Solicitors/Patent and Trade Mark Agents  
Practice Restricted to Intellectual Property Law

July 11, 2000

Micheline Gravelle B.Sc., M.Sc. (Immunol.)  
416 957 1682 mgravelle@bereskinparr.com

Your Reference: n/a  
Our Reference: 10242-32

Commissioner for Patents and Trademarks  
Washington, D.C. 20231  
U.S.A.

Dear Sirs:


**Re: PRELIMINARY AMENDMENT**  
**United States National Phase Entry of PCT/CA99/00005**  
**Entitled: Composition Containing Propargylamine**  
**for Enhancing Cancer Therapy**  
**Inventors: R.C. Warrington, I.A. Paterson and A.A. Boulton**

We are simultaneously entering national phase in the United States for PCT/CA99/00005. The present letter is to file a Preliminary Amendment to the application. Please amend the application as follows:

**In the Claims:**

Please delete claims 1-51 currently of record and add new claims 52-80 as follows:

52. (New) A method for enhancing the activity of an antineoplastic drug comprising administering an effective amount of a propargylamine to an animal in need thereof, wherein the propargylamine is of the general formula I



wherein

x is an integer ranging from 0 to 13;

y is an integer ranging from 0 to 5;

z is 1;

R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are the same or different and represent hydrogen or a straight chain or branched lower alkyl; and

R' and R'' are the same or different and represent hydrogen, phenyl or a halogen and pharmaceutically acceptable salts thereof.

53. (New) A method according to claim 52 wherein the propargylamine increases the sensitivity of a tumor to an antineoplastic drug.

54. (New) A method according to claim 53 wherein the tumor is a drug resistant tumor.


55. (New) A method according to claim 52 wherein the propargylamine protects normal cells from the cytotoxic effects of the antineoplastic drug.

56. (New) A method according to claim 52 wherein y is 1.

57. (New) A method according to claim 56 wherein the propargylamine is R-2-heptyl-methyl propargylamine (R-2HMP).

58. (New) A method according to claim 52 wherein the propargylamine is selected from the group consisting of N-(1-Propyl) N-methylpropargylamine; N-(2-Propyl) N-methylpropargylamine; N-(1-Butyl) N-methylpropargylamine; N-(1-Pentyl) N-methylpropargylamine; N-(1-Hexyl) N-methylpropargylamine; N-(1-Heptyl) N-methylpropargylamine; N-(1-Octyl) N-methylpropargylamine; N-(1-Nonyl) N-methylpropargylamine; N-(1-Decyl) N-methylpropargylamine; N-(1-Undecyl) N-methylpropargylamine; N-(1-Dodecyl) N-methylpropargylamine; (R)-N-(2-Butyl) N-methylpropargylamine; (R)-N-(2-Pentyl) N-methylpropargylamine; (R)-N-(2-Hexyl) N-methylpropargylamine; (R)-N-(2-Heptyl) N-methylpropargylamine; (R)-N-(2-Octyl) N-methylpropargylamine; (R)-N-(2-Decyl) N-methylpropargylamine; (R)-N-(2-Undecyl) N-methylpropargylamine; and (R)-N-(2-Dodecyl) N-methylpropargylamine.

59. (New) A method according to claim 52, wherein y is 0.
60. (New) A method according to claim 59 wherein the propargylamine is R-2-heptyl-propargylamine (R-2 HPA).
61. (New) A method according to claim 59 wherein the propargylamine is selected from the group consisting of N-(1-Propyl) propargylamine; N-(2-Propyl) propargylamine; N-(1-Butyl) propargylamine; N-(1-Pentyl) propargylamine; N-(1-Hexyl) propargylamine; N-(1-Heptyl) propargylamine; N-(1-Octyl) propargylamine; N-(1-Nonyl) propargylamine; N-(1-Decyl) propargylamine; N-(1-Undecyl) propargylamine; N-(1-Dodecyl) propargylamine; (R)-N-(2-Butyl) propargylamine; (R)-N-(2-Pentyl) propargylamine; (R)-N-(2-Hexyl) propargylamine; (R)-N-(2-Heptyl) propargylamine; (R)-N-(2-Octyl) propargylamine; (R)-N-(2-Decyl) propargylamine; (R)-N-(2-Undecyl) propargylamine; and (R)-N-(2-Dodecyl) propargylamine.
62. (New) A method according to claim 52 wherein the propargylamine is R-deprenyl.
63. (New) A method according to claim 52 wherein the propargylamine is R-desmethyldeprenyl.
64. (New) A method according to claim 52 wherein the animal is a human.
65. (New) A method for enhancing the activity of an antineoplastic drug comprising administering an effective amount of Rasagiline to an animal in need thereof.
66. (New) A method according to claim 52 wherein the propargylamine is a chiral compound and is the R-enantiomer.
67. (New) A method for treating cancer comprising administering an antineoplastic drug and an effective amount of a propargylamine to an animal in need thereof, wherein the propargylamine is of the general formula I



wherein

x is an integer ranging from 0 to 13;

y is an integer ranging from 0 to 5;

z is 1;


R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are the same or different and represent hydrogen or a straight chain or branched lower alkyl; and

R' and R'' are the same or different and represent hydrogen, phenyl or a halogen and pharmaceutically acceptable salts thereof.

68. (New) A method according to claim 67 wherein the antineoplastic drug is selected from the group consisting of cytosine arabinoside, cis-platinum, cyclophosphamide, adriamycin, daunomycin, and 5-fluorouracil.

69. (New) A method according to claim 66 wherein the propargylamine is a chiral compound and is the R-enantiomer.

70. (New) A pharmaceutical composition for treating cancer comprising an antineoplastic drug and an effective amount of a propargylamine of the general formula I:



wherein

x is an integer ranging from 0 to 13;

y is an integer ranging from 0 to 5;

z is 1;

R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are the same or different and represent hydrogen or a straight chain or branched lower alkyl; and

R' and R'' are the same or different and represent hydrogen, phenyl or a halogen and pharmaceutically acceptable salts thereof.

71. (New) A pharmaceutical composition according to claim 70 wherein y is 1.

72. (New) A pharmaceutical composition according to claim 71 wherein the propargylamine is R-2-heptyl-methyl propargylamine (R-2HMP).

73. (New) A pharmaceutical composition according to claim 71 wherein the propargylamine is selected from the group consisting of N-(1-Propyl) N-methylpropargylamine; N-(2-Propyl) N-methylpropargylamine; N-(1-Butyl) N-methylpropargylamine; N-(1-Pentyl) N-methylpropargylamine; N-(1-Hexyl) N-methylpropargylamine; N-(1-Heptyl) N-methylpropargylamine; N-(1-Octyl) N-methylpropargylamine; N-(1-Nonyl) N-methylpropargylamine; N-(1-Decyl) N-methylpropargylamine; N-(1-Undecyl) N-methylpropargylamine; N-(1-Dodecyl) N-methylpropargylamine; (R)-N-(2-Butyl) N-methylpropargylamine; (R)-N-(2-Pentyl) N-methylpropargylamine; (R)-N-(2-Hexyl) N-methylpropargylamine; (R)-N-(2-Heptyl) N-methylpropargylamine; (R)-N-(2-Octyl) N-methylpropargylamine; (R)-N-(2-Decyl) N-methylpropargylamine; (R)-N-(2-Undecyl) N-methylpropargylamine; and (R)-N-(2-Dodecyl) N-methylpropargylamine.

74. (New) A pharmaceutical composition according to claim 70, wherein y is 0.

75. (New) A pharmaceutical composition according to claim 74 wherein the propargylamine is R-2-heptyl-propargylamine (R-2HPA).

76. (New) A pharmaceutical composition according to claim 74 wherein said propargylamine is selected from the group consisting of N-(1-Propyl) propargylamine; N-(2-Propyl) propargylamine; N-(1-Butyl) propargylamine; N-(1-Pentyl) propargylamine; N-(1-Hexyl) propargylamine; N-(1-Heptyl) propargylamine; N-(1-Octyl) propargylamine; N-(1-Nonyl) propargylamine; N-(1-Decyl) propargylamine; N-(1-Undecyl) propargylamine; N-(1-Dodecyl) propargylamine; (R)-N-(2-Butyl) propargylamine; (R)-N-(2-Pentyl) propargylamine; (R)-N-(2-Hexyl) propargylamine;

(R)-N-(2-Heptyl) propargylamine; (R)-N-(2-Octyl) propargylamine; (R)-N-(2-Octyl) propargylamine; (R)-N-(2-Decyl) propargylamine; (R)-N-(2-Undecyl) propargylamine; and (R)-N-(2-Dodecyl) propargylamine.

77. (New) A pharmaceutical composition according to claim 70 wherein the propargylamine is a chiral compound and is the R-enantiomer.

78. (New) A pharmaceutical composition according claim 70 wherein the propargylamine is R-deprenyl.

79. (New) A pharmaceutical composition according to claim 70 wherein the propargylamine is R-desmethyldeprenyl.

80. (New) A pharmaceutical composition for treating cancer comprising an antineoplastic drug and Rasagiline.

#### **REMARKS**

By the present amendment, the claims have been amended in order to enter similar amendments that were made in response to the Written Opinion but were not entered by the Examiner. In general, the claims have been amended in order to specify that the "propargylamine" is of the general Formula I as recited in the claims. The claims have also been amended in order to replace "z is an integer ranging from 0 to 5" with "z is 1". Support for this amendment can be found in the specific propargylamines recited throughout the application. The claims have further been amended to delete the "use" claims. For ease of referral, new claims 52-69 generally correspond to original claims 34-51 and new claims 70-80 generally correspond to original claims 22-33. Original claims 1-21 have been deleted.

The amendments have been made without prejudice and for the purposes of advancing prosecution. Applicant reserves the right to file any of the deleted subject matter in a further application. The Preliminary Amendment does not contain new matter.



Entry of the above preliminary amendment is respectfully requested. Please calculate the claim fee for the application once the amendment has been entered.

Respectfully submitted,

**R.C. Warrington, I.A. Paterson and A.A. Boulton**



---

Micheline Gravelle  
Registration No. 40,261

Dated: July 11, 2000

Bereskin & Parr  
Box 401, 40 King Street West  
Toronto, Ontario, Canada  
M5H 3Y2

Tel. (416) 364-7311

COMPOSITION CONTAINING PROPARGYLAMINE FOR ENHANCING CANCER THERAPYFIELD OF THE INVENTION

The present invention relates to a method for enhancing  
5 cancer therapy by administering an effective amount of an antineoplastic  
modulator. Preferred antineoplastic modulators are propargylamines  
including aliphatic propargylamines and aromatic propargylamines. The  
invention also includes a pharmaceutical composition for enhancing the  
10 treatment of cancer comprising an effective amount of an antineoplastic  
modulator of the present invention in admixture with a suitable diluent  
or carrier.

BACKGROUND OF THE INVENTION

Cancer is a collection of diseases involving inappropriate and  
unregulated growth of cells in the body. The aim of chemical therapy  
15 (chemotherapy) of cancer is to introduce a chemical (antineoplastic drug)  
which will kill the cancerous cells but will not damage normal cells. The  
early rationale for the development of conventional antineoplastic drugs  
was that such agents would act selectively on cells undergoing cell  
division; since cancerous cells were thought to be invariably dividing  
20 more rapidly than normal cells in the body, it was believed that this would  
offer some therapeutic selectivity. However, antineoplastic agents  
collectively have the lowest therapeutic indices of any class of drugs used  
in humans. This lack of selectivity leads to the severe side effects  
associated with cancer chemotherapy; the major dose-limiting  
25 consideration for use of these agents is toxicity to bone marrow.  
Furthermore, the poor selectivity of these agents means they must be used  
at sub-optimal doses. The latter, in turn, may cause the development of a  
variety of drug resistance traits by cancerous cells. Thus, many types of  
cancers are ultimately unresponsive to chemotherapy and are therefore  
30 incurable.

Notwithstanding such limitations, chemotherapy remains  
the only and thus the most important treatment option for disseminated

- 2 -

cancers. Despite decades of effort to find more effective and less toxic agents, the poor response of patients to conventional anticancer drugs and the limitations arising from intrinsic or acquired drug-resistance continue to limit the chemotherapeutic approach. It is estimated that over 50% of patients with advanced cancer will fail to respond, or will relapse from their initial response to chemotherapy, and will thus ultimately succumb to their disease. Given the prevalence and severity of disseminated disease, improving the chemotherapeutic treatment modality nevertheless remains a crucial objective of cancer research (1).

One novel and potentially major means of improving the chemotherapeutic modality of cancer treatment would be to improve the selectivity of the currently-available agents. To the degree to which selectivity could be improved, such an approach would diminish the toxic side effects and allow treatment with more appropriate doses of antineoplastics which, in turn, would diminish the inadvertent selection of drug-resistance variants during treatment. If, in addition, such a strategy would circumvent drug-resistance traits of either the intrinsic or acquired types, it would diminish all of the major, known limitations to conventional cancer chemotherapy. Remarkably, such an approach has been developed and verified to have all of these advantages in experimental chemotherapeutic models (2- 17). Termed the modulator approach for improving cancer chemotherapy, this novel strategy solves the major limitations otherwise associated with the use of conventional antineoplastics.

An antineoplastic modulator is a chemical which modifies the action of an antineoplastic drug, improving the selectivity, and therefore efficacy of the antineoplastic drug. An antineoplastic modulator acts, simultaneously, to advantage in three ways: i), it protects non-cancerous (normal) tissue from the toxic effects of the antineoplastic drug; ii), it increases the ability of the antineoplastic drug to kill cancerous cells, and iii), it suppresses the drug resistance traits exhibited by many cancerous cells.

- 3 -

The present inventors have prepared many novel propargylamines as described in United States Patent No. 5,169,868 and 5,840,979. The inventors have shown that the novel propargylamines are useful as MAO-B inhibitors and are useful in treating various  
5 neuropsychiatric disorders including Parkinson's disease, Alzheimer's disease, depression, attention deficit disorder, hyperactive disorders as well as other aging-associated diseases.

Surprisingly, the present inventors have found that the propargylamines are also useful as antineoplastic modulators and can  
10 enhance the effect of antineoplastic drugs.

#### **SUMMARY OF THE INVENTION**

Broadly stated, the present invention relates to a method of enhancing cancer therapy by administering an effective amount of a propargylamine. The present inventors have shown that  
15 propargylamines enhance the killing of tumor cells by antineoplastic drugs and protect normal cells from the cytotoxic effects of antineoplastic drugs. Consequently, propargylamines are well-suited to enhance any chemotherapy regime and can increase the effectiveness while reducing the side-effects of cancer therapy.

20 In one aspect, the present invention relates to a method for enhancing the effect of an antineoplastic drug comprising administering an effective amount of a propargylamine to an animal in need thereof.

In another aspect, the present invention relates to a method of increasing the sensitivity of a tumor to an antineoplastic drug  
25 comprising administering an effective amount of propargylamine of the invention to an animal in need thereof.

In a further aspect, the present invention provides a method of protecting normal cells from the cytotoxic effects of an antineoplastic drug comprising administering an effective amount of a propargylamine  
30 of the invention to an animal in need thereof.

In a further aspect, the present invention relates to a method for treating cancer comprising administering an antineoplastic drug and

- 4 -

an effective amount of a propargylamine of the invention to an animal in need thereof.

The present invention also includes a use of a propargylamine of the present invention for the preparation of a medicament to be used in the therapeutic methods described herein.

The present invention further includes a pharmaceutical composition useful for enhancing cancer therapy comprising an effective amount of a propargylamine of the invention in admixture with a suitable diluent or carrier.

The pharmaceutical compositions of the present invention may be useful in (i) enhancing the activity of an antineoplastic drug, (ii) increasing the sensitivity of a tumor to an antineoplastic drug and/or (iii) protecting normal cells from the cytotoxic effects of an antineoplastic drug.

The present invention also includes a pharmaceutical composition useful for treating cancer comprising an antineoplastic drug and an effective amount of a propargylamine of the present invention.

Other features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

## **BRIEF DESCRIPTION OF THE DRAWINGS**

The invention will now be described in relation to the drawings in which:

Figure 1 is graph showing the RATIO of various antineoplastic modulators versus the concentration of the antineoplastic modulator. The definition of RATIO is provided in Example 1.

- 5 -

Figure 2 is a graph showing the relative cell survival of normal bone marrow versus time, in the presence of various modulators. HISOL=histindinol, cis=cisplatinum, 2HPA=R-2HPA.

Figure 3 is a graph showing the relative cell survival of cancer cells versus time, in the presence of various modulators.


#### DETAILED DESCRIPTION OF THE INVENTION

Broadly stated, the present invention relates to a method of enhancing cancer therapy by administering an effective amount of a propargylamine. The present inventors have shown that propargylamines enhance the killing of tumor cells by antineoplastic drugs and protect normal cells from the cytotoxic effects of antineoplastic drugs. In addition, the propargylamines have been shown to overcome a drug-resistance attribute of tumor cells. *In vivo* data is included which verifies that these three powerful attributes of the approach are operative in live, tumor bearing animals. Consequently, propargylamines are well-suited to enhance any chemotherapy regime.

#### Propargylamines

The propargylamines that may be included in the methods, uses and compositions of the present invention include any propargylamine that can enhance the effect of an antineoplastic drug. The ability of a propargylamine to enhance the effect of an antineoplastic can be determined using the assays described in the Examples or using other assays known in the art.

In one embodiment, the propargylamine is of the general formula I



wherein

x is an integer ranging from 0 to 13;

y is an integer ranging from 0 to 5;

- 6 -

z is an integer ranging from 0 to 5;

R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are the same or different and represent hydrogen or a straight chain or branched lower alkyl; and

R' and R'' are the same or different and represent hydrogen, phenyl or a halogen and pharmaceutically acceptable salts thereof.

Preferably the lower alkyl has between 1 and 4 carbon atoms and the halogen atom is selected from fluorine, chlorine, bromine and iodine. More preferably, the lower alkyl is selected from methyl.

In another embodiment, the propargylamine is of the general formula I wherein y is 1 and the pharmaceutically acceptable salts thereof. A preferred propargylamine of the formula I wherein y is 1 is R-2-heptyl-methylpropargylamine (R-2HMP).

Other propargylamines of the formula I wherein y is 1 include:

- 15 N-(1-Propyl) N-methylpropargylamine;
- N-(2-Propyl) N-methylpropargylamine;
- N-(1-Butyl) N-methylpropargylamine;
- N-(1-Pentyl) N-methylpropargylamine;
- N-(1-Hexyl) N-methylpropargylamine;
- 20 N-(1-Heptyl) N-methylpropargylamine;
- N-(1-Octyl) N-methylpropargylamine;
- N-(1-Nonyl) N-methylpropargylamine;
- N-(1-Decyl) N-methylpropargylamine;
- N-(1-Undecyl) N-methylpropargylamine;
- 25 N-(1-Dodecyl) N-methylpropargylamine;
- (R)-N-(2-Butyl) N-methylpropargylamine;
- (R)-N-(2-Pentyl) N-methylpropargylamine;
- (R)-N-(2-Hexyl) N-methylpropargylamine;
- (R)-N-(2-Heptyl) N-methylpropargylamine;
- 30 (R)-N-(2-Octyl) N-methylpropargylamine;
- (R)-N-(2-Octyl) N-methylpropargylamine;
- (R)-N-(2-Decyl) N-methylpropargylamine;

(R)-N-(2-Undecyl) N-methylpropargylamine; and  
(R)-N-(2-Dodecyl) N-methylpropargylamine.

In yet another embodiment, the propargylamine is of the general formula I, described above, wherein y is 0, and the  
5 pharmaceutically acceptable salts thereof. A preferred propargylamine of the formula I where y=0, is R-2-heptyl-propargylamine (R-2HPA).

Other compounds of the formula I, wherein y is 0, include:

- N-(1-Propyl) propargylamine;
- N-(2-Propyl) propargylamine;
- 10 N-(1-Butyl) propargylamine;
- N-(1-Pentyl) propargylamine;
- N-(1-Hexyl) propargylamine;
- N-(1-Heptyl) propargylamine;
- N-(1-Octyl) propargylamine;
- 15 N-(1-Nonyl) propargylamine;
- N-(1-Decyl) propargylamine;
- N-(1-Undecyl) propargylamine;
- N-(1-Dodecyl) propargylamine;
- (R)-N-(2-Butyl) propargylamine;
- 20 (R)-N-(2-Pentyl) propargylamine;
- (R)-N-(2-Hexyl) propargylamine;
- (R)-N-(2-Heptyl) propargylamine;
- (R)-N-(2-Octyl) propargylamine;
- (R)-N-(2-Octyl) propargylamine;
- 25 (R)-N-(2-Decyl) propargylamine;
- (R)-N-(2-Undecyl) propargylamine; and
- (R)-N-(2-Dodecyl) propargylamine.

The preferred propargylamines of the chiral compounds of the formula I are the R-enantiomers.


- 30 In a further embodiment, the propargylamine is R-deprenyl. R-deprenyl is a compound of the formula I wherein R<sub>1</sub> is methyl, R<sub>2</sub> is



hydrogen, R<sup>~</sup> is phenyl, R<sup>'</sup> is hydrogen, x is 1, y is 1, z is 1 and R<sub>3</sub> is hydrogen.

In another embodiment, the propargylamine is R-desmethyldeprenyl. R-desmethyldeprenyl is a compound of the formula I  
5 wherein R<sub>1</sub> is methyl, R<sub>2</sub> is hydrogen, R<sup>~</sup> is phenyl, R<sup>'</sup> is hydrogen, x is 1, y is 0, z is 1 and R<sub>3</sub> is hydrogen.

In yet another embodiment, the propargylamine is Rasagiline having the following formula II:



All of the above described propargylamines may be  
10 collectively referred to as "the propargylamines of the invention".

The propargylamines of the present invention may be prepared using techniques known in the art. For example, the aliphatic propargylamines may be prepared as described in the inventors United States Patent No. 5,169,868 and 5,840,979 both which are incorporated  
15 herein by reference in their entirety. Briefly, the compounds may be prepared by condensing propargyl bromide with a chiral aliphatic amine or N-methylamine in the presence of a base and recovering the desired compound. Preferably the R-enantiomers are prepared.

### Therapeutic Methods and Uses

20 As hereinbefore mentioned, the present invention relates to a method for enhancing the effect of an antineoplastic drug comprising administering an effective amount of a propargylamine of the invention to an animal in need thereof. The invention also includes a use of a propargylamine of the invention to enhance the effect of an antineoplastic  
25 drug.

The term "effective amount" as used herein means an amount effective, at dosages and for periods of time necessary to achieve the desired result.

The term "animal" as used herein means any member of the animal kingdom including all mammals, birds, fish, reptiles and amphibians. Preferably, the animal to be treated is a mammal, more preferably a human.

5           One method by which the propargylamines of the invention may enhance the effect of an antineoplastic drug is by increasing the sensitivity of the tumor to the drug. Accordingly, in one aspect, the present invention relates to a method of increasing the sensitivity of a tumor to an antineoplastic drug comprising administering an effective  
10   amount of propargylamine of the invention to an animal in need thereof. The tumor may be one that is resistant to cancer therapy such as a multidrug resistant tumor or a radioresistant tumor. This aspect also includes a use of a propargylamine of the invention to increase the sensitivity of a tumor to an antineoplastic agent.

15           Another method by which the propargylamines of the invention may enhance the effect of an antineoplastic drug is by protecting normal cells from the cytotoxic effects of the drug. Accordingly, in another aspect, the present invention provides a method of protecting normal cells from the cytotoxic effects of an antineoplastic drug comprising  
20   administering an effective amount of a propargylamine of the invention to an animal in need thereof. This aspect also includes a use of a propargylamine of the invention to protect normal cells from the cytotoxic effects of an antineoplastic drug.

25           In a further aspect, the present invention relates to a method for treating cancer comprising administering an antineoplastic drug and an effective amount of a propargylamine of the invention to an animal in need thereof. This aspect includes a use of (a) a propargylamine and (b) an antineoplastic drug to treat cancer.

30           The propargylamines of the invention can be used to enhance the treatment of all forms of cancer or malignant diseases for which chemotherapy is a bona fide treatment option. These malignancies include, but are not limited to, leukemias, lymphomas (Hodgkins and

- 10 -

non-Hodgkins), plasmacytomas, histiocytomas, melanomas, adenomas, sarcomas, carcinomas of solid tissues, hypoxic tumours, squamous cell carcinomas, genitourinary cancers such as cervical and bladder cancer, hematopoietic cancers, head and neck cancers, and nervous system

5 cancers. Treatment with the propargylamine modulators may allow for treatment of tumors that are resistant to chemotherapy. The latter are diverse, but one common, well-studied example is the so-called multi-drug resistant (MDR) tumor cells. MDR tumors include adenocarcinomas, neuroblastoma cells, leukemias, lymphomas, breast

10 cancer and ovarian cancer cells. Treatment with the propargylamine modulators may also allow for more effective radiotherapy of tumours that currently respond poorly to radiotherapy such as adenocarcinomas of the bowel and lung.

Antineoplastic drugs which may be potentiated or enhanced

15 by the propargylamine modulators can be any antineoplastic drug including known, conventional drugs as well as those yet to be identified. Examples of classes of antineoplastic agents include antimetabolites, alkylating agents, antimicrobial antineoplastics, antimicrotubule agents, cisplatin and its derivatives and the topoisomerase interactive agents.

20 In particular, chemotherapeutic agents amenable to this modulatory effect may include but are not limited to, adriamycin, BCNU and CCNU (i.e., bis (2-chloroethyl)-3-cyclohexyl-1-nitrosurea and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, respectively, bleomycin sulfate, camptothecin, carmustine, chlorambucil, cisplatin, cyclophosphamide, cytosine arabinoside,

25 daunomycin/daunorubicin, dacarbazine, doxorubicin, 5-fluorouracil, melphalan, mitomycin, mitoxantrone hydrochloride, etoposide, streptozocin and taxol and taxol derivatives.

Although the propargylamines of the invention may be administered before, after and/or concurrently with the antineoplastic

30 drug, they are likely best administered prior to chemotherapy.

### Pharmaceutical Compositions

The propargylamines of the invention may be incorporated into a pharmaceutical composition which may be useful in enhancing the activity of an antineoplastic drug, increasing the sensitivity of a tumor to an antineoplastic drug and/or protecting normal cells from the cytotoxic effects of an antineoplastic drug. The pharmaceutical composition may additionally include an antineoplastic drug and may be useful for treating cancer.

The pharmaceutical compositions of the invention can be prepared by per se known methods for the preparation of pharmaceutically acceptable compositions which can be administered to patients, and such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable vehicle. Suitable vehicles are described, for example, in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985). The pharmaceutical compositions of the invention can be for oral, topical, rectal, parenteral, local, intravenous, inhalant or intracerebral use. They may be in solid or semisolid form, for example pills, tablets, creams, gelatin capsules, capsules, suppositories, soft gelatin capsules, gels, membranes, tubelets. For parenteral and intracerebral uses, those forms for intramuscular or subcutaneous administration can be used, or forms for infusion or intravenous or intracerebral injection can be used, and can therefore be prepared as solutions of the active compounds or as powders of the active compounds to be mixed with one or more pharmaceutically acceptable excipients or diluents, suitable for the aforesaid uses and with an osmolarity which is compatible with the physiological fluids. For local use, those preparations in the form of creams or ointments for topical use or in the form of sprays should be considered; for inhalant uses, preparations in the form of sprays, for example nose sprays, should be considered. Dosages to be administered depend on individual needs, on the desired effect and on the chosen route of administration, but daily dosages to humans by subcutaneous,

- 12 -

intramuscular, intravenous or intracerebral injection generally vary between about 100 ng and 100 µg of active substance per Kg body weight, preferably between 1 µg and 50 µg per Kg body weight for the aliphatic propargylamines. For aromatic propargylamines, the above doses may be increased ten fold.

The following non-limiting examples are illustrative of the present invention:

### EXAMPLES

#### EXAMPLE 1

#### 10 *In Vitro* Protocol for Assessing the Capacity of Various Compounds to Modulate Cisplatinum Toxicity

The protocol detailed below can be used for any normal/tumorigenic cell pair which will attach to plastic. Non-adherent lines (which includes most tumor cells, including NW16; consult references 5-10) require quantitation in soft agar. The present experiments are based on i) rat2 cells, a phenotypically normal, established rat fibroblast line and, ii) a tumorigenic derivative thereof, NW16 cells, which are rat2 cells transformed by a Fujinami sarcoma virus oncogene (see work of A. Pawson and P130<sup>gag-fps</sup>). Rat2 and NW16 cells are maintained in a sub-confluent randomly-proliferating state in Dulbecco's modified minimal essential media with 10% (vol/vol) calf serum in plates incubated at 37°C in a humidified CO<sub>2</sub> (10%) incubator. All experiments reported rely on clonogenic cell survival assays (see references 4-6). Assays using rat2 (normal cells) were performed as follows: cells are exposed, in 10 cm culture dishes, to various drugs in media plus serum for varying lengths of time; seeding is at varying cell numbers, over log<sub>10</sub> ranges, depending upon the degree of killing anticipated. [For the figure presented, incubation was for 72 hours prior to washing and assessment of clonogenic survival]. Both control and the experimental cultures are then gently washed, twice, with phosphate buffered saline, then once more with media minus serum, and then left in media plus serum, undisturbed until macroscopic colonies appear (7-9 days of incubation). The colonies are

then fixed and stained with saturated methylene blue in 50% methanol and counted. The number of colonies, evaluated from 2 or more sets of duplicate cultures seeded at initial densities differing by factors of 10, are determined and converted to relative number of colonies, using the 0-hour control value as 1.0. Assays of NW16 cells were similar; however, because these cells are poorly adherent, following drug exposure, the washing procedure is modified, as is the quantitation of survivors step. In the latter case, quantitation requires plating the cells in soft agar (references 5-10).

#### 10 Presentation of Results by "RATIO" Method

A simplified presentation of the data, by the RATIO method, is shown in Figure 1. By dividing the relative cell survival (R.C.S.) value obtained in cultures which have been exposed to the combination of anticancer drug (in this case, cisplatinum) and modulator by the corresponding R.C.S. value obtained for the anticancer drug alone reveals both the nature and the magnitude of the effect mediated by the modulator. Ratios greater than unity indicate that the modulator has conferred a protective response, whereas ratios less than unity indicate an enhanced cell killing.

#### 20 Results

As can be seen from Figure 1, R-2-heptyl-propargylamine (R-2HPA), the desmethyl metabolite of R-2-heptyl-methyl propargylamine (R-2HMP), and R-2HMP (the pro-drug) are effective, over a wide concentration range ( $10^{-7}$  -  $10^{-15}$  M), at protecting normal fibroblasts which are p53 dependent. R-2HPA is the more potent. R-Deprenyl whilst active, is less efficacious over a more limited concentration range ( $10^{-7}$  -  $10^{-13}$  M). The usually inactive pro-drug isomer S-2HMP is also inactive in this assay. In the tumorigenic cells (mutants in which p53 is absent) it can be seen that enhanced killing by cisplatinum occurs in the range ( $10^{-11}$  -  $10^{-15}$  M) but with a reversal to a protective effect when the concentration of R-2HMP is  $10^{-9}$ M or greater.

### Summary

R-2HMP and R-2HPA both protect normal cells and enhance the killing of tumor cells in the presence of cisplatinum in this *in vitro* fibroblast model. The protection and the enhanced killing occur in the  
5 10<sup>-11</sup> - 10<sup>-15</sup> M range. R-Deprenyl was also effective over a more limited concentration, in the 10<sup>-7</sup> to 10<sup>-13</sup> M range. Since L-histidinol exhibits similar properties (although higher doses are required) in this and several other *in vitro* and *in vivo* paradigms, and in the presence of other anticancer drugs, it is reasonable to predict that R-2HMP, R-2HPA and the  
10 other aliphatic propargylamines, by analogy, will also exhibit activity in these other systems.

### EXAMPLE 2

#### *In Vivo* Assessment of Anticancer Drug Modulators: Effects of R-2HPA

Seven groups of mice were treated and assessed in this model  
15 as follows:

1. Nil control (1 mouse)
2. P388 control (1 mouse)
3. Cisplatinum (5 mice)
4. Histidinol (2 mice)
- 20 5. Histidinol + cisplatinum (5 mice)
6. R-2HPA (4 mice)
7. R-2HPA + cisplatinum (5 mice)

P388 cells (1 million) were injected into the tail vein of 22 female DBA/2J mice (Protocol first developed in reference 6 and 8). The  
25 mice were then randomly divided into the above groups and injected (ip) with drugs 96h later. Doses were cisplatinum 0.2 mg at 0 hour; Histidinol 5 mg/injection and R-2HPA 0.38 ug/injection; administered 5 times at -2, 0, +2, +4, and +6 hours. 48 h after drug treatment, cells from the femurs of the mice were harvested, washed and plated (at log<sub>10</sub> dilutions) so as to  
30 allow quantitative and specific relative cell survival values to be generated for the responses of normal femoral bone marrow cells (specifically,

CFU-C/GM or granulocyte/macrophage precursor cells) and clonogenic P388 leukemia cells (8).

As can be seen in Figure 2, both histidinol and R-2HPA were effective at protecting normal bone marrow cells, whereas in Figure 3, it can be seen that both histidinol and R-2HPA enhanced the killing by cisplatin of P388 cells. It should be emphasized that the P388 leukemic line is substantially resistant to the cisplatin (relative to the responses of the CFU-c/GM cells). This is an example of the poor therapeutic index common to conventional antineoplastics. In this example, the cisplatin, when used alone, can be seen to be about 100-times more effective at killing the crucial normal marrow cells than it is for killing the intrafemoral leukemia (tumor) cells. In the presence of the modulators histidinol and R-2HPA, the therapeutic index of cisplatin is vastly improved; thus, the toxicity to the marrow cells is essentially eliminated and the toxicity to the leukemia cells is increased by almost a 1000-fold. In other words, both histidinol and R-2HPA are simultaneously protecting the most vulnerable normal cells from cancer drug toxicity and simultaneously circumventing a profound drug-resistance trait. That these effects are observed *in vivo* (i.e., in live animals) and in the same tissue of those animals cannot be over-emphasized in terms of its potential capacity to improve chemotherapy, in as much as it reveals clearly and dramatically the ability of modulators to improve selectivity, efficacy and to circumvent the problem of drug-resistance shown by tumor cells. It can also be seen that this remarkable effect is obtained with R-2HPA at the low dose of 0.38 ug, producing a therapeutic index of about 50,000 between the protection of healthy normal cells and the killing of the cancerous cells. This effect is known to be p53 dependent vis a vis histidinol and it is likely to be the same with R-2HPA.

The modulator strategy has been shown to be remarkably effective in many *in vivo* tumor models (4-6; 7-11), in numerous types of human cancer cells (12,13) and in many kinds of drug resistance traits (5; 16,17). Consequently, considering the data cited herein, it is predicted that



- 16 -

the use of propargylamines as antineoplastic modulators will improve the chemotherapeutic management of a wide variety of human malignant disease types which will include non-resistant, intrinsic and acquired drug-resistance types. The modulator approach has been validated  
5 experimentally to markedly improve treatment of malignancies of myeloid origin (leukemias, lymphomas, and cancers of "blood cell" origin; (7-10) and for disseminated or metastatic disease (11); these are the situations wherein chemotherapy is often the only available clinical  
10 treatment option, the least responsive to treatment and/or the most prone to failure due to either intrinsic or acquired drug-resistance and hence incurable status.

While the present invention has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the invention is not limited to the disclosed  
15 examples. To the contrary, the invention is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.

All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each  
20 individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

## FULL CITATIONS FOR REFERENCES REFERRED TO IN THE SPECIFICATION

- 1) M R Grever and B A Chabner, Cancer Drug Discovery and Development. in : *Cancer: Principles and Practice of Oncology*, 5th Ed., VT  
5 DeVita, S Hellman and SA Rosenberg, editors. Lippincott-Raven Press 1997.
- 2) RC Warrington, 1978. Selective Killing of Oncogenic Human Cells Cocultivated with Normal Human Fibroblasts. *Journal of the National Cancer Institute*, 61, 69-72.
- 10 3) RC Warrington and W.D. Fang, 1982. Protection of Cultured Mouse Spleen Cells From the Cytotoxic Action of AraC and 5FU by L-Histidinol. *Journal of the National Cancer Institute*, 68, 279-286.
- 4) RC Warrington, 1993. Modulation of anticancer drug toxicity by L-histidinol: a route for improving human cancer chemotherapy?  
15 *Drugs of the Future*, 18, 743-749.
- 5) RC Warrington, 1992. L-Histidinol in Experimental Cancer Chemotherapy: Improving the Selectivity and Efficacy of Anticancer Drugs, Eliminating Metastatic Disease and Reversing the Multidrug-Resistant Phenotype. *Biochemistry and Cell Biology* 70,  
20 365-375.
- 6) RC Warrington, 1986. A Novel Approach for Improving the Efficacy of Experimental Cancer Chemotherapy using Combinations of Anticancer Drugs and L-histidinol. *Anticancer Research*, 6, no. 3, 451-464.
- 7) R.C. Warrington, T.G. Muzyka and W.D. Fang, 1984.  
25 Histidinol-Mediated Improvement in the Specificity of

1- $\beta$ -D-arabinofuranosylcytosine and 5-fluorouracil in L1210 Leukemia Bearing Mice. *Cancer Research*, 44, 2929-2937.


- 8) R.C. Warrington and W.D. Fang, 1985. Histidinol-mediated Enhancement of the Specificity of Two Anticancer Drugs in Mice Bearing  
5 Leukemic Bone Marrow Disease. *Journal of the National Cancer Institute*, 74, 1071-1077.
- 9) R.C. Warrington, I Cheng and W.D. Fang, 1985. Effects of L-histidinol on the susceptibility of P815 mastocytoma cells to selected anticancer drugs in vitro and in vivo. *Journal of the National Cancer*  
10 *Institute*, 78: 11177 1183.
- 10) R.C. Warrington and W.D. Fang, 1989. L-Histidinol Improves the Selectivity and Efficacy of Alkylating Agents and Daunomycin in Mice with P388 Leukemia. *British Journal of Cancer*, 60, 652-656, 1989.
- 11) R.C. Warrington and W.D. Fang, 1991. Improved treatment  
15 of disseminated B 16f10 melanoma in mice with anticancer drugs in combination with L-histidinol. *Anticancer Research* 11, 1869-1874.
- 12) R C Warrington, I Cheng, L Zhang and WD Fang, 1993. L-Histidinol increases the vulnerability of cultured human leukemia and lymphoma cells to anticancer drugs. *Anticancer Res.* 13: 2107-2112.
- 20 13) RC Warrington, I Cheng and W D Fang, 1994. Susceptibility of human colon carcinoma cells to anticancer drugs is enhanced by L-histidinol. *Anticancer Research*, 14 : 367-372.
- 14) RC Warrington, WD Fang, L Zhang, M Shieh and MH Saier, 1996. L-Histidinol selectively modulates daunomycin toxicity in normal  
25 and tumorigenic kidney epithelial cells. *Anticancer Res.* 16: 3629-3634.

- 19 -

- 15) RC Warrington, WD Fang, L Zhang, M Shieh and MH Saier, 1996. Mimetics of L-histidinol which selectively modulate daunomycin toxicity in normal and tumorigenic epithelial cells. *Anticancer Res.* 16: 3635-3640.
- 5 16) RC Warrington and W.D. Fang, 1989. Reversal of the Multidrug-Resistant Phenotype of Chinese Hamster Ovary Cells by L-histidinol. *Journal of the National Cancer Institute*, 81, 798-803
- 17) RC Warrington, WD Fang and L Zhang, 1996. L-Histidinol reverses resistance of cisplatin and other antineoplastics in a  
10 tumorigenic epithelial cell line. *Anticancer Res.* 16: 3641-3645.

WE CLAIM:

1. A use of a propargylamine to enhance the activity of an antineoplastic drug.
2. A use according to claim 1 wherein the propargylamine increases the sensitivity of a tumor to the antineoplastic drug.
3. A use according to claim 2 wherein the tumor is a drug resistant tumor.
4. A use according to claim 1 wherein the propargylamine protects normal cells from the cytotoxic effects of the antineoplastic drug.
5. A use of (a) a propargylamine and (b) an antineoplastic drug to treat cancer.
6. A use according to any one of claims 1-5 wherein the propargylamine is of the general formula I



wherein

- x is an integer ranging from 0 to 13;
- y is an integer ranging from 0 to 5;
- z is an integer ranging from 0 to 5;
- R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are the same or different and represent hydrogen or a straight chain or branched lower alkyl; and
- R' and R'' are the same or different and represent hydrogen, phenyl or a halogen and pharmaceutically acceptable salts thereof.

- 21 -

7. A use according to claim 6 wherein y is 1.

8. A use according to claim 7 wherein the propargylamine is R-2-heptyl-methyl propargylamine (R-2HMP).

9. A use according to claim 7 wherein the propargylamine is  
5 selected from the group consisting of N-(1-Propyl)  
N-methylpropargylamine; N-(2-Propyl) N-methylpropargylamine;  
N-(1-Butyl) N-methylpropargylamine; N-(1-Pentyl)  
N-methylpropargylamine; N-(1-Hexyl) N-methylpropargylamine;  
N-(1-Heptyl) N-methylpropargylamine; N-(1-Octyl)  
10 N-methylpropargylamine; N-(1-Nonyl) N-methylpropargylamine;  
N-(1-Decyl) N-methylpropargylamine; N-(1-Undecyl)  
N-methylpropargylamine; N-(1-Dodecyl) N-methylpropargylamine;  
(R)-N-(2-Butyl) N-methylpropargylamine; (R)-N-(2-Pentyl)  
N-methylpropargylamine; (R)-N-(2-Hexyl) N-methylpropargylamine;  
15 (R)-N-(2-Heptyl) N-methylpropargylamine; (R)-N-(2-Octyl)  
N-methylpropargylamine; (R)-N-(2-Decyl) N-methylpropargylamine;  
(R)-N-(2-Undecyl) N-methylpropargylamine; and (R)-N-(2-Dodecyl)  
N-methylpropargylamine.

20 10. A use according to claim 6 wherein y is 0.

11. A use according to claim 10 wherein the propargylamine is R-2-heptyl-propargylamine (R-2HPA).

12. A use according to claim 10 wherein said propargylamine is  
selected from the group consisting of N-(1-Propyl) propargylamine;  
25 N-(2-Propyl) propargylamine; N-(1-Butyl) propargylamine; N-(1-Pentyl)  
propargylamine; N-(1-Hexyl) propargylamine; N-(1-Heptyl)  
propargylamine; N-(1-Octyl) propargylamine; N-(1-Nonyl)

- 22 -

propargylamine; N-(1-Decyl) propargylamine; N-(1-Undecyl)  
propargylamine; N-(1-Dodecyl) propargylamine; (R)-N-(2-Butyl)  
propargylamine; (R)-N-(2-Pentyl) propargylamine; (R)-N-(2-Hexyl)  
propargylamine; (R)-N-(2-Heptyl) propargylamine; (R)-N-(2-Octyl)  
5 propargylamine; (R)-N-(2-Octyl) propargylamine; (R)-N-(2-Decyl)  
propargylamine; (R)-N-(2-Undecyl) propargylamine; and (R)-N-(2-Dodecyl)  
propargylamine.

13. A use according to any one of claims 1 to 7, 9, 10 or 12  
wherein the propargylamine is a chiral compound and is the R-  
10 enantiomer.

14. A use according to any one of claims 1-6 wherein the  
propargylamine is R-deprenyl.

15. A use according to any one of claims 1-6 wherein the  
propargylamine is R-desmethyldeprenyl.

15 16. A use according to any one of claims 1-5 wherein the  
propargylamine is Rasagiline.

17. A use according to any one of claims 1-16 wherein the animal  
is a human.

18. A use according to any one of claims 1-17 wherein the  
20 antineoplastic drug is selected from the group consisting of cytosine  
arabioside, cis-platinum, cyclophosphamide, adriamycin, daunomycin,  
and 5-fluorouracil.

19. A pharmaceutical composition for enhancing the activity of  
an antineoplastic drug comprising an effective amount of a  
25 propargylamine in admixture with a suitable diluent or carrier.


- 23 -

20. A pharmaceutical composition according to claim 19 for increasing the sensitivity of a tumor to the antineoplastic drug.

21. A pharmaceutical composition according to claim 19 for protecting normal cells from the cytotoxic effects of the antineoplastic  
5 drug.

22. A pharmaceutical composition for treating cancer comprising an antineoplastic drug and an effective amount of a propargylamine.

23. A pharmaceutical composition according to any one of claims 19 to 22, wherein the propargylamine is of the general formula I:



15 wherein

x is an integer ranging from 0 to 13;

y is an integer ranging from 0 to 5;

z is an integer ranging from 0 to 5;

20  $\text{R}_1$ ,  $\text{R}_2$  and  $\text{R}_3$  are the same or different and represent hydrogen or a straight chain or branched lower alkyl; and

$\text{R}'$  and  $\text{R}''$  are the same or different and represent hydrogen, phenyl or a halogen and pharmaceutically acceptable salts thereof.

24. A pharmaceutical composition according to claim 23 wherein y is 1.

25 25. A pharmaceutical composition according to claim 24 wherein the propargylamine is R-2-heptyl-methyl propargylamine (R-2HMP).



- 24 -

26. A pharmaceutical composition according to claim 24 wherein the propargylamine is selected from the group consisting of N-(1-Propyl) N-methylpropargylamine; N-(2-Propyl) N-methylpropargylamine; N-(1-Butyl) N-methylpropargylamine; N-(1-Pentyl) N-methylpropargylamine; N-(1-Hexyl) N-methylpropargylamine; N-(1-Heptyl) N-methylpropargylamine; N-(1-Octyl) N-methylpropargylamine; N-(1-Nonyl) N-methylpropargylamine; N-(1-Decyl) N-methylpropargylamine; N-(1-Undecyl) N-methylpropargylamine; N-(1-Dodecyl) N-methylpropargylamine; (R)-N-(2-Butyl) N-methylpropargylamine; (R)-N-(2-Pentyl) N-methylpropargylamine; (R)-N-(2-Hexyl) N-methylpropargylamine; (R)-N-(2-Heptyl) N-methylpropargylamine; (R)-N-(2-Octyl) N-methylpropargylamine; (R)-N-(2-Decyl) N-methylpropargylamine; (R)-N-(2-Undecyl) N-methylpropargylamine; and (R)-N-(2-Dodecyl) N-methylpropargylamine.

27. A pharmaceutical composition according to claim 23, wherein y is 0.

28. A pharmaceutical composition according to claim 27 wherein the propargylamine is R-2-heptyl-propargylamine (R-2HPA).

29. A pharmaceutical composition according to claim 27 wherein said propargylamine is selected from the group consisting of N-(1-Propyl) propargylamine; N-(2-Propyl) propargylamine; N-(1-Butyl) propargylamine; N-(1-Pentyl) propargylamine; N-(1-Hexyl) propargylamine; N-(1-Heptyl) propargylamine; N-(1-Octyl) propargylamine; N-(1-Nonyl) propargylamine; N-(1-Decyl) propargylamine; N-(1-Undecyl) propargylamine; N-(1-Dodecyl) propargylamine; (R)-N-(2-Butyl) propargylamine; (R)-N-(2-Pentyl) propargylamine; (R)-N-(2-Hexyl) propargylamine; (R)-N-(2-Heptyl)

- 25 -


propargylamine; (R)-N-(2-Octyl) propargylamine; (R)-N-(2-Octyl) propargylamine; (R)-N-(2-Decyl) propargylamine; (R)-N-(2-Undecyl) propargylamine; and (R)-N-(2-Dodecyl) propargylamine.

30. A pharmaceutical composition according to any one of claims  
5 19 to 24, 26, 27 or 29 wherein the propargylamine is a chiral compound and is the R-enantiomer.
31. A pharmaceutical composition according to any one of claims  
19 to 23, wherein the propargylamine is R-deprenyl.
32. A pharmaceutical composition according to any one of claims  
10 19 to 23, wherein the propargylamine is R-desmethyldeprenyl.
33. A pharmaceutical composition according to any one of claims  
19 to 22, wherein the propargylamine is Rasagiline.
34. A method for enhancing the activity of an antineoplastic  
15 drug comprising administering an effective amount of a propargylamine to an animal in need thereof.
35. A method according to claim 34 wherein the propargylamine  
increases the sensitivity of a tumor to an antineoplastic drug.
36. A method according to claim 35 wherein the tumor is a drug  
resistant tumor.
- 20 37. A method according to claim 34 wherein the propargylamine  
protects normal cells from the cytotoxic effects of the antineoplastic drug.

- 26 -

38. A method for treating cancer comprising administering an antineoplastic drug and an effective amount of a propargylamine to an animal in need thereof.

39. A method according to any one of claims 34 to 38, wherein  
5 the propargylamine is of the general formula I



wherein

x is an integer ranging from 0 to 13;

y is an integer ranging from 0 to 5;

z is an integer ranging from 0 to 5;

15  $\text{R}_1$ ,  $\text{R}_2$  and  $\text{R}_3$  are the same or different and represent hydrogen or a straight chain or branched lower alkyl; and

$\text{R}'$  and  $\text{R}''$  are the same or different and represent hydrogen, phenyl or a halogen and pharmaceutically acceptable salts thereof.

40. A method according to claim 39 wherein y is 1.

20 41. A method according to claim 40 wherein the propargylamine is R-2-heptyl-methyl propargylamine (R-2HMP).

42. A method according to claim 39 wherein the propargylamine is selected from the group consisting of N-(1-Propyl) N-methylpropargylamine; N-(2-Propyl) N-methylpropargylamine;  
25 N-(1-Butyl) N-methylpropargylamine; N-(1-Pentyl) N-methylpropargylamine; N-(1-Hexyl) N-methylpropargylamine; N-(1-Heptyl) N-methylpropargylamine; N-(1-Octyl)

- 27 -

N-methylpropargylamine; N-(1-Nonyl) N-methylpropargylamine;  
N-(1-Decyl) N-methylpropargylamine; N-(1-Undecyl)  
N-methylpropargylamine; N-(1-Dodecyl) N-methylpropargylamine;  
(R)-N-(2-Butyl) N-methylpropargylamine; (R)-N-(2-Pentyl)  
5 N-methylpropargylamine; (R)-N-(2-Hexyl) N-methylpropargylamine;  
(R)-N-(2-Heptyl) N-methylpropargylamine; (R)-N-(2-Octyl)  
N-methylpropargylamine; (R)-N-(2-Octyl) N-methylpropargylamine;  
(R)-N-(2-Decyl) N-methylpropargylamine; (R)-N-(2-Undecyl)  
N-methylpropargylamine; and (R)-N-(2-Dodecyl)  
10 N-methylpropargylamine.

43. A method according to claim 39, wherein y is 0.

44. A method according to claim 43 wherein the propargylamine  
is R-2-heptyl-propargylamine (R-2 HPA).

45. A method according to claim 43 wherein the propargylamine  
15 is selected from the group consisting of N-(1-Propyl) propargylamine;  
N-(2-Propyl) propargylamine; N-(1-Butyl) propargylamine; N-(1-Pentyl)  
propargylamine; N-(1-Hexyl) propargylamine; N-(1-Heptyl)  
propargylamine; N-(1-Octyl) propargylamine; N-(1-Nonyl)  
propargylamine; N-(1-Decyl) propargylamine; N-(1-Undecyl)  
20 propargylamine; N-(1-Dodecyl) propargylamine; (R)-N-(2-Butyl)  
propargylamine; (R)-N-(2-Pentyl) propargylamine; (R)-N-(2-Hexyl)  
propargylamine; (R)-N-(2-Heptyl) propargylamine; (R)-N-(2-Octyl)  
propargylamine; (R)-N-(2-Octyl) propargylamine; (R)-N-(2-Decyl)  
propargylamine; (R)-N-(2-Undecyl) propargylamine; and (R)-N-(2-Dodecyl)  
25 propargylamine.

46. A method according to any one of claims 34 to 39, wherein  
the propargylamine is R-deprenyl.

- 28 -

47. A method according to any one of claims 34 to 39, wherein the propargylamine is R-desmethyldeprenyl.
48. A method according to any one of claims 34 to 38, wherein the propargylamine is Rasagiline.
- 5 49. A method according to any one of claims 34 to 48, wherein the animal is a human.
50. A method according to any one of claims 34 to 49 wherein the antineoplastic drug is selected from the group consisting of cytosine arabinoside, cis-platinum, cyclophosphamide, adriamycin, daunomycin,  
10 and 5-fluorouracil.
51. A method according to any one of claims 34 to 40, 42, 43 and 45 wherein the propargylamine is a chiral compound and is the R-enantiomer.


**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 33/24, 31/675, 31/505, 31/70, 31/13</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/36076</b>
			<b>(43) International Publication Date:</b> 22 July 1999 (22.07.99)
<b>(21) International Application Number:</b> PCT/CA99/00005 <b>(22) International Filing Date:</b> 13 January 1999 (13.01.99) <b>(30) Priority Data:</b> 60/071,023 13 January 1998 (13.01.98) US <b>(71) Applicant (for all designated States except US):</b> UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES INC. [CA/CA]; 117 Science Place, Saskatoon, Saskatchewan S7N 5C8 (CA). <b>(71) Applicant (for US only):</b> THE CANADA TRUST COMPANY (executor for the deceased inventor) [GB/CA]; Suite 800, 421 7th Avenue, Calgary, Alberta T2P 3Y8 (CA). <b>(72) Inventor:</b> PATERSON, I., Alick (deceased). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> WARRINGTON, R., C. [CA/CA]; University of Saskatchewan, Neuropsychiatry Research Unit A, 114 Medical Research Building, 103 Wiggins Road, Saskatoon, Saskatchewan S7N 5E4 (CA). BOULTON, Alan, A. [CA/CA]; 1905 Spadina Crescent East, Saskatoon, Saskatchewan S7K 0C9 (CA).			<b>(74) Agent:</b> BERESKIN & PARR; 40th floor, 40 King Street West, Toronto, Ontario M5H 3Y2 (CA).  <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> COMPOSITION CONTAINING PROPARGYLAMINE FOR ENHANCING CANCER THERAPY			
<b>(57) Abstract</b> <p>Antineoplastic drug modulators are described. The specific modulators referred to are propargylamines which can enhance the cytotoxic effects of antineoplastic drugs on cancer cells while protecting normal cells from damage. The propargylamine modulators can be used to increase the selectivity and effectiveness of conventional antineoplastic drugs, to reduce the unwanted side-effects of cancer chemotherapy, to improve effectiveness of cancer chemotherapy, to improve treatment of cancers for which treatment is otherwise ineffective, to improve therapy of cancers otherwise unresponsive or poorly responsive due to drug-resistance and/or toxicity limited treatment regimens and to render effective chemotherapy for previously untreatable cancers.</p>			

1/3

**FIGURE 1**



2/3

**FIGURE 2**



3/3

## P388 LEUKEMIA




FIGURE 3

**DECLARATION FOR UTILITY OR  
DESIGN  
PATENT APPLICATION  
(37 CFR 1.63)**

☐ Declaration  
Submitted  
With Initial  
Filing  
OR  
☒ Declaration  
Submitted after Initial  
Filing (surcharge  
(37 CFR 1.16 (e))  
required)

Attorney Docket Number 10242-32  
First Named Inventor R C. Warrington

**COMPLETE IF KNOWN**

Application Number 09/600,125  
Filing Date July 12, 2000  
Group Art Unit  
Examiner Name

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Composition Containing Propargylamine For Enhancing Cancer Therapy

the specification of which (Title of the Invention)

☐ is attached hereto

OR

☒ was filed on (MM/DD/YYYY) 07/12/2000 as United States Application Number or PCT International

Application Number 09/600,125 and was amended on (MM/DD/YYYY) (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims as amended specifically referred to above

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or of any PCT international application having a filing date before that of the application on which priority is claimed

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY) Country	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto

[Page 1 of 2]

**Burden Hour Statement** This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231

## DECLARATION — Utility or Design Patent Application

Direct all correspondence to ☒ Customer Number **1059** OR ☐ Correspondence address below

Name

Address

City

State

ZIP

Country

Telephone

Fax

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVENTOR:

☐ A petition has been filed for this unsigned inventor

Given Name  
(first and middle [if any])

R.C.

Family Name  
or Surname Warrington

Inventor's  
Signature

Date  
Apr 13/02

Saskatoon

Saskatchewan

Canada

Canadian

Residence: City

State

Country

Citizenship

718 Albert Avenue

Mailing Address

Saskatoon

Saskatchewan

S7N  
1G9

Canada

City

State

Zip

Country

NAME OF SECOND INVENTOR:

☐ A petition has been filed for this unsigned inventor

Given Name  
(first and middle [if any])

Alick

Family Name  
or Surname Paterson (deceased)

Inventor's  
Signature

THE CANADA TRUST COMPANY, EXECUTOR

Date  
APR 2, 2002

Saskatoon (Deceased)

Saskatchewan  
(Deceased)

Canada  
(Dec)

United Kingdom  
(Deceased)

Saskatoon (Legal Representative)

Saskatchewan  
(Legal Rep)

Canada  
(Legal Rep)

No citizenship  
(Legal Rep)

Residence: City

State

Country

Citizenship

802-12 Street East (deceased)

The Canada Trust Company 170-2<sup>nd</sup> Ave South (Legal Representative)

Mailing Address

Saskatoon (Deceased)

Saskatchewan  
(Deceased)

S7N  
0H7  
(Dec'd)

Canada (Deceased)

Saskatoon (Legal Representative)

Saskatchewan  
(Legal Rep)

S7K  
1K5  
(Leg Rep)

Canada (Legal Rep.)

City

State

Zip

Country

☒ Additional inventors are being named on the 1 supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.

Please type a plus sign (+) inside this box →



Approved for use through 10/31/2002 OMB 0651-0032

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

**DECLARATION**
**ADDITIONAL INVENTOR(S)**  
**Supplemental Sheet**  
 Page 1 of 1

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
Alan A.		Boulton	
Inventor's Signature		Date	
		Mar 3 '02	
Residence: City	Saskatoon	State	Saskatchewan
Country	Canada	Citizenship	Canadian
Mailing Address			
1905 Spadina Crescent East			
Mailing Address			
City	Saskatoon	State	Saskatchewan
ZIP	S7K 0C9	Country	Canadian
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
Inventor's Signature		Date	
Residence: City		State	
Country		Citizenship	
Mailing Address			
Mailing Address			
City		State	
Zip		Country	
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
Inventor's Signature		Date	
Residence: City		State	
Country		Citizenship	
Mailing Address			
Mailing Address			
City		State	
Zip		Country	

Burden Hour Statement. This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.